Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Organomegaly

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Organomegaly. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-000440-24 Sponsor Protocol Number: SDX-101-03 Start Date*: 2004-08-24
    Sponsor Name:Cephalon UK Limited
    Full Title: A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination with Chlorambucil, and that of Chlorambucil alone, in Patients with Chronic ...
    Medical condition: Chronic Lymphocytic Leukemia (CLL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003667-11 Sponsor Protocol Number: M15-550 Start Date*: 2016-08-01
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Open-Label, Single Arm, Phase 3B, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (VENICE I)
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) SE (Completed) BE (Completed) NL (Completed) DE (Completed) AT (Completed) IE (Completed) PT (Completed) FI (Completed) DK (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001097-15 Sponsor Protocol Number: M15-889 Start Date*: 2016-09-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (Venice II)
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-004339-19 Sponsor Protocol Number: UTX-TGR-204 Start Date*: 2017-02-16
    Sponsor Name:TG Therapeutics
    Full Title: A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002328-10 Sponsor Protocol Number: TIGEM1-MPSVI Start Date*: 2018-10-29
    Sponsor Name:FONDAZIONE TELETHON
    Full Title: A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects with Mucopolysaccharidosis type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the human ARSB gene to Liver.
    Medical condition: The clinical trial will be conducted on patients with Mucopolysaccharidosis Type VI. MPS VI is characterized by growth retardation, corneal clouding, cardiac valve disease, organomegaly, skeletal d...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004998-53 Sponsor Protocol Number: OMB116024 Start Date*: 2013-02-05
    Sponsor Name:National and Kapodistrian University of Athens
    Full Title: A phase II study of the efficacy of the combination of ofatumumab with fludarabine and cyclophosphamide in patients with relapsed or refractory Waldenström’s Macroglobulinemia.
    Medical condition: Relapsed or refractory Waldenström’s Macroglobulinemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000407-20 Sponsor Protocol Number: APHP201454 Start Date*: 2021-09-22
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Full Title: Treatment of nonsevere sporadic Hemophagocytosis Lymphohistiocytosis (HLHs) with ITACITINIB: a phase II prospective trial.
    Medical condition: Adults patients having non severe sporadic Hemophagocytosis Lymphohistiocytosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001033-27 Sponsor Protocol Number: REMODEL-WM3 Start Date*: 2016-08-25
    Sponsor Name:FILO
    Full Title: REMODEL - WM3 An Open Label non-randomized Phase II Study exploring «chemo-free » treatment association with Idelalisib + Obinutuzumab in Patient with relapsed/refractory Waldenstrom’s Macroglobuli...
    Medical condition: Waldenstrom’s Macroglobulinemia (MW)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001321-31 Sponsor Protocol Number: 24032020 Start Date*: 2020-04-11
    Sponsor Name:Hospital Universitario de Fuenlabrada
    Full Title: Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients wit...
    Medical condition: Pneumonia due to SARS Cov2 (COVID-19)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006292-20 Sponsor Protocol Number: GS-US-312-0115 Start Date*: 2012-07-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chroni...
    Medical condition: Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) IT (Completed) PL (Completed) CZ (Completed) HU (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2005-001651-37 Sponsor Protocol Number: OGT 918-011 Start Date*: 2005-10-27
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A phase IV, open-label, non comparative, multi-center study to evaluate the long term efficacy and safety and tolerability of oral miglustat as a maintenance after a switch from Enzyme Replacement ...
    Medical condition: Gaucher disease is the most common of the glycosphingolipid storage diseases and has autosomal recessive inheritance. For a more precise description, please refer to page 16 of the protocol: 1 BA...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-000506-37 Sponsor Protocol Number: ECWM-1 Start Date*: 2014-10-31
    Sponsor Name:University Hospital Ulm
    Full Title: Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia
    Medical condition: Waldenström's Macroglobulinemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) IT (Ongoing) PT (Prematurely Ended) SE (Ongoing) GR (Restarted) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002752-16 Sponsor Protocol Number: GCT3009-01 Start Date*: 2020-11-17
    Sponsor Name:Genmab Holding B.V.
    Full Title: Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma – A First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts
    Medical condition: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended) NL (Completed) FR (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018780-42 Sponsor Protocol Number: OMB113676 Start Date*: 2010-10-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
    Medical condition: Indolent B-Cell Non-Hodgkin's Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Prematurely Ended) BG (Prematurely Ended) BE (Completed) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-005053-20 Sponsor Protocol Number: ML39235 Start Date*: 2018-02-06
    Sponsor Name:Polish Myeloma Consortium
    Full Title: A multicenter, single-arm, phase II study to evaluate a safety and efficacy of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed/refractory Waldenström Macroglobul...
    Medical condition: Waldenström's macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10047802 Waldenstrom's macroglobulinaemias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005758-36 Sponsor Protocol Number: UTX-TGR-304 Start Date*: 2016-10-28
    Sponsor Name:TG Therapeutics
    Full Title: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chr...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004932-19 Sponsor Protocol Number: OMB110911 Start Date*: 2009-01-27
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    17.0 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    17.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    17.0 10005329 - Blood and lymphatic system disorders 10024295 Leukaemias chronic lymphocytic HLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008959 Chronic lymphocytic leukaemia (in remission) PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) SE (Completed) BE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006293-72 Sponsor Protocol Number: GS-US-312-0117 Start Date*: 2012-05-08
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS 1101) for Previously Treated Chronic Lymphocytic Leukemia A C...
    Medical condition: Chronic lymphocytic leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014876-23 Sponsor Protocol Number: EZN-2208-04 Start Date*: 2010-05-20
    Sponsor Name:Enzon Pharmaceuticals, Inc
    Full Title: A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC)
    Medical condition: mestatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000880-28 Sponsor Protocol Number: IELSG36 Start Date*: 2012-10-25
    Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)
    Full Title: Bendamustine and Rituximab for the treatment of Splenic Marginal Zone Lymphoma. The IELSG-36 phase II prospective study.
    Medical condition: Splenic Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062113 Splenic marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 17:50:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA